{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:57:31Z","timestamp":1770721051294,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.025","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:31:43Z","timestamp":1761931903000},"page":"e172-e179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8971-269X","authenticated-orcid":false,"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto Ruiz","family":"Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.025_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clml.2025.10.025_bib0003","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000529341","article-title":"Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors","volume":"101","author":"Fujiwara","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2025.10.025_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular Toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology State-of-the-art Review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0007","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.clml.2025.10.025_bib0008","article-title":"Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2025.10.025_bib0009","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","article-title":"An overview of the role of carfilzomib in the treatment of multiple myeloma","volume":"18","author":"Ziogas","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2025.10.025_bib0010","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-025-06240-1","article-title":"Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed \/refractory multiple myeloma","volume":"104","author":"Garcia-Guinon","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.10.025_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051655","article-title":"Current treatment strategies for multiple myeloma at first relapse","volume":"14","author":"Mavrothalassitis","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.10.025_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-025-01256-2","article-title":"Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis","volume":"15","author":"Dong","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.025_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70178","article-title":"Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma","volume":"9","author":"Landgren","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.10.025_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121943","article-title":"Upfront Anti-CD38 monoclonal antibody-based quadruplet therapy for multiple myeloma: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2025.10.025_bib0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/bloodadvances.2024014417","article-title":"MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma","volume":"9","author":"Bhutani","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.025_bib0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.025_bib0017","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ajh.27314","article-title":"Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.025_bib0018","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/dc15-2237","article-title":"Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?","volume":"39","author":"Smith","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clml.2025.10.025_bib0019","unstructured":"Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry."},{"key":"10.1016\/j.clml.2025.10.025_bib0020","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2025.10.025_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0022","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0023","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.025_bib0024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.025_bib0025","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3324\/haematol.2021.278399","article-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)","volume":"106","author":"Yong","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.025_bib0026","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","article-title":"KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma","volume":"57","author":"Gaballa","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.10.025_bib0027","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma","volume":"13","author":"Tan","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70038","article-title":"Balancing the risk of cardiotoxicity outcomes in treatment selection for multiple myeloma: a retrospective multicenter evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)","volume":"6","author":"Lee","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.10.025_bib0029","article-title":"Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management","volume":"16","author":"Gao","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2025.10.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113228","article-title":"Carfilzomib-specific proteasome beta5\/beta2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system","volume":"28","author":"Mendez-Lopez","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.clml.2025.10.025_bib0031","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available Proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.clml.2025.10.025_bib0032","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clml.2025.10.025_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142353","article-title":"Validation of the HFA-ICOS score for Carfilzomib-induced cardiotoxicity in multiple myeloma: a real-life perspective study","volume":"17","author":"Astarita","year":"2025","journal-title":"Cancers"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:25Z","timestamp":1770650305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502504265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S215226502504265X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}